Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphohistiocytosis, Hemophagocytic 1Epstein-Barr Virus Infections 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Etoposide 3Dexamethasone 2Cyclophosphamide 2Alemtuzumab 2tocilizumab 1sintilimab 1pegaspargase 1Whole-Body Irradiation 1Vincristine 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Gemcitabine 1EPOCH protocol 1Doxorubicin 1Cytarabine 1Calcium Dobesilate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphohistiocytosis, Hemophagocytic × EPOCH protocol × Clear all
NCT01818908 2019-02-15

Trial of DA-EPOCH Regimen for NHL With HLH

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
50 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡